Apalutamide: First Global Approval

被引：52
作者：
Al-Salama, Zaina T. [1 ]
机构：
[1] Springer, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2018年 / 78卷 / 06期
关键词：
RESISTANT PROSTATE-CANCER; ANTITUMOR-ACTIVITY; ARN-509; ANTIANDROGEN; SAFETY;
D O I：
10.1007/s40265-018-0900-z
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Apalutamide (Erleada (TM)) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC). It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens. In February 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC). Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochemically-relapsed PC. This article summarizes the milestones in the development of apalutamide leading to this first approval in nmCRPC.
引用
收藏
页码：699 / 705
页数：7
相关论文
共 14 条
[1]  
[Anonymous], ANN ONCOL S6
[2]   Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective [J].
Cancian, Madeline ;
Renzulli, Joseph F., II .
UROLOGY, 2018, 116 :13-16
[3]   ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment [J].
Clegg, Nicola J. ;
Wongvipat, John ;
Joseph, James D. ;
Tran, Chris ;
Ouk, Samedy ;
Dilhas, Anna ;
Chen, Yu ;
Grillot, Kate ;
Bischoff, Eric D. ;
Cal, Ling ;
Aparicio, Anna ;
Dorow, Steven ;
Arora, Vivek ;
Shao, Gang ;
Qian, Jing ;
Zhao, Hong ;
Yang, Guangbin ;
Cao, Chunyan ;
Sensintaffar, John ;
Wasielewska, Teresa ;
Herbert, Mark R. ;
Bonnefous, Celine ;
Darimont, Beatrice ;
Scher, Howard I. ;
Smith-Jones, Peter ;
Klang, Mark ;
Smith, Nicholas D. ;
De Stanchina, Elisa ;
Wu, Nian ;
Ouerfelli, Ouathek ;
Rix, Peter J. ;
Heyman, Richard A. ;
Jung, Michael E. ;
Sawyers, Charles L. ;
Hager, Jeffrey H. .
CANCER RESEARCH, 2012, 72 (06) :1494-1503
[4]   A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 [J].
Joseph, James D. ;
Lu, Nhin ;
Qian, Jing ;
Sensintaffar, John ;
Shao, Gang ;
Brigham, Dan ;
Moon, Michael ;
Maneval, Edna Chow ;
Chen, Isan ;
Darimont, Beatrice ;
Hager, Jeffrey H. .
CANCER DISCOVERY, 2013, 3 (09) :1020-1029
[5]  
Koukourakis MI, 2018, ANTI-CANCER DRUG, DOI [10.1097/CAD, DOI 10.1097/CAD]
[6]  
MCKENZIE M, 2016, CAN UROL ASS J S1, V10, pS73
[7]   Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide [J].
Rathkopf, D. E. ;
Smith, M. R. ;
Ryan, C. J. ;
Berry, W. R. ;
Shore, N. D. ;
Liu, G. ;
Higano, C. S. ;
Alumkal, J. J. ;
Hauke, R. ;
Tutrone, R. F. ;
Saleh, M. ;
Maneval, E. Chow ;
Thomas, S. ;
Ricci, D. S. ;
Yu, M. K. ;
de Boer, C. J. ;
Trinh, A. ;
Kheoh, T. ;
Bandekar, R. ;
Scher, H. I. ;
Antonarakis, E. S. .
ANNALS OF ONCOLOGY, 2017, 28 (09) :2264-2271
[8]   Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone [J].
Rathkopf, Dana E. ;
Antonarakis, Emmanuel S. ;
Shore, Neal D. ;
Tutrone, Ronald F. ;
Alumkal, Joshi J. ;
Ryan, Charles J. ;
Saleh, Mansoor ;
Hauke, Ralph J. ;
Bandekar, Rajesh ;
Maneval, Edna Chow ;
de Boer, Carla J. ;
Yu, Margaret K. ;
Scher, Howard I. .
CLINICAL CANCER RESEARCH, 2017, 23 (14) :3544-3551
[9]   Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer [J].
Rathkopf, Dana E. ;
Morris, Michael J. ;
Fox, Josef J. ;
Danila, Daniel C. ;
Slovin, Susan F. ;
Hager, Jeffrey H. ;
Rix, Peter J. ;
Maneval, Edna Chow ;
Chen, Isan ;
Goenen, Mithat ;
Fleisher, Martin ;
Larson, Steven M. ;
Sawyers, Charles L. ;
Scher, Howard I. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) :3525-+
[10]  
Rathkopf DE, 2015, J CLIN ONCOL C S, V33
12